Delayed-enhancement magnetic resonance imaging at 3.0T using 0.15mmol/kg of contrast agent for the assessment of chronic myocardial infarction.
A recent international, multicenter, double-blinded, randomized trial shows delayed-enhanced magnetic resonance imaging (DE-MRI) using contrast doses of ≥0.2mmol/kg is effective in the detection and assessment of myocardial infarction (MI), and 0.1mmol/kg is not enough; intermediate doses between 0.1 and 0.2mmol/kg have not been tested. The aim of this study was to prospectively test the performance of DE-MRI using 0.15mmol/kg of contrast agent for the detection of MI. A total of 31 consecutive patients with chronic MI underwent DE-MRI at 3.0T using both 0.15mmol/kg and 0.2mmol/kg of contrast agent in random order and on separate days. Infarction segment and infarction size were compared on DE-MRI images using a 17-segment model. Bland-Altman analysis was used to analyze correlation and agreement between global infarct sizes. DE-MRI showed enhanced myocardium in all the 31 patients with chronic MI. There was no significant difference between the 0.15mmol/kg and 0.2mmol/kg images in all 31 patients based on the infarction segment (7.87±2.72 vs. 7.81±2.64, respectively; p=0.33). There was no significant difference between the infarction size obtained from 0.15mmol/kg acquisition and that from 0.2mmol/kg acquisition (16.3±7.8% vs. 16.4±7.9%, respectively; p=0.87). A strong correlation between the infarction size obtained from 0.15mmol/kg acquisition and that from 0.2mmol/kg acquisition was indicated through Bland-Altman analysis. DE-MRI at 3.0T using 0.15mmol/kg of contrast agent is effective for the assessment of MI.